Navigation Links
Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting

SAN DIEGO, April 09, 2007 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, and its collaborators will present clinical and preclinical study results involving its cancer drug candidates at the American Association for Cancer Research Annual Meeting in Los Angeles April 14-18. Four posters and two minisymposia will highlight the novel mechanisms and anti-tumor activity in several tumor models for three Nereus compounds: the small molecule proteasome inhibitor NPI-0052, the tumor vascular disrupting agent (VDA) NPI-2358, and a new preclinical candidate NPI-1387, a highly selective, small molecule IKK modulator. Nereus will also present preliminary data from its Phase I dose escalation trial of NPI-2358 in patients with solid tumors and lymphoma.

In addition to the Company's single agent studies, Nereus collaborators from the University of Texas M.D. Anderson Cancer Center will describe research demonstrating markedly enhanced potency and apoptosis in human leukemia cells treated with NPI-0052 and various histone deacetylase (HDAC) inhibitors.

Nereus researchers and collaborators will make the following presentations at AACR:

Sunday, April 15, 2007

#1445: Sensitization of B-NHL resistant tumor cells overexpressing Bcl-xL to TRAIL-induced apoptosis by the novel proteasome inhibitor Salinosporamide A (NPI-0052)

Eriko Suzuki, Michael Palladino, Genhong Chen, Benjamin Bonavida. David Geffen School of Medicine at UCLA, Los Angeles, CA, Nereus Pharmaceuticals, San Diego, CA

#1453: Rituximab-mediated sensitization of resistant B-NHL cell lines to the proteasome inhibitor NPI-0052-induced apoptosis: pivotal role of PTEN induction and inhibition of Bcl-xL

Eriko Suzuki, Michael Palladino, Benjamin Bonavida. David Geffen School of Medicine at UCLA, Los Angeles, CA, Nereus Pharmaceuticals, San Diego, CA


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 Symmetry Medical Inc. (NYSE: ... medical device solutions, including orthopedic implants, surgical instruments, ... it has signed a definitive agreement to acquire ... design, development and manufacturing of electrosurgical instruments and ...
... Aug. 3, 2011 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... were $111.2 million, a 17 percent increase over revenues ... Results for all periods of fiscal 2010 ...
Cached Medicine Technology:Symmetry Medical to Acquire Olsen Medical 2Symmetry Medical to Acquire Olsen Medical 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 2Thoratec Reports Second Quarter Revenue Increase of 17 Percent 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 4Thoratec Reports Second Quarter Revenue Increase of 17 Percent 5Thoratec Reports Second Quarter Revenue Increase of 17 Percent 6Thoratec Reports Second Quarter Revenue Increase of 17 Percent 7Thoratec Reports Second Quarter Revenue Increase of 17 Percent 8Thoratec Reports Second Quarter Revenue Increase of 17 Percent 9Thoratec Reports Second Quarter Revenue Increase of 17 Percent 10Thoratec Reports Second Quarter Revenue Increase of 17 Percent 11Thoratec Reports Second Quarter Revenue Increase of 17 Percent 12Thoratec Reports Second Quarter Revenue Increase of 17 Percent 13Thoratec Reports Second Quarter Revenue Increase of 17 Percent 14Thoratec Reports Second Quarter Revenue Increase of 17 Percent 15Thoratec Reports Second Quarter Revenue Increase of 17 Percent 16Thoratec Reports Second Quarter Revenue Increase of 17 Percent 17Thoratec Reports Second Quarter Revenue Increase of 17 Percent 18Thoratec Reports Second Quarter Revenue Increase of 17 Percent 19
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... A new type of sensor for people with diabetes is ... saliva instead of blood, researchers report. Scientists at Brown ... it using artificial saliva. It uses light, metal and a ... "Everybody knows that diabetics have to prick their fingers ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... Calif, Nov. 3 BioMarin Pharmaceutical,Inc. (Nasdaq: ... Morquio Clinical,Assessment Program (MorCAP) for patients with the ... Morquio A Syndrome. MorCAP is,designed to augment available ... function and other parameters in affected patients.,BioMarin expects ...
... Services Cited as Pivotal to ... Efficiency Statewide, NASHVILLE, Tenn., Nov. 3 Emdeon, ... for the healthcare industry,has been named the electronic data ... Association (MHA). Emdeon was selected,through a competitive bidding process ...
... Va., Nov. 3 "When my father was formally,diagnosed ... book,pamphlet, and newspaper article I could get my hands ... Conversation About Alzheimer,s" (published by,AuthorHouse -- http://www.authorhouse.com ). ... I told myself that once I knew the facts, ...
... its inaugural list of the top 100, ... a leading,provider of kidney care services for those ... named in the top 100 of Modern Healthcare,s,Best ... on the list, is,the only nationwide healthcare services ...
... Nov. 3 Sabin Robbins, a,75-year old prostate ... Florida to benefit from treatment with new RapidArc(TM),radiotherapy ... Cancer Center of Boynton Beach, Florida. RapidArc, which ... ), unleashes the precision of,intensity-modulated radiation therapy (IMRT) ...
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... novel anti-infective products, today,announced that it has ... VCG,& Associates will serve as MiddleBrook,s strategic ... pricing and reimbursement, contract,administration, national account management ...
Cached Medicine News:Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4Health News:Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange 2Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 3Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
... Neuroprene™ soft supports are a ... to proprioceptive taping for common orthopedic ... help provide specific compression and lateral ... receptors (proprioceptors) in the skin and ...
... low-profile, wraparound, hinged knee product with an ... who have difficulty applying a sleeve, the ... ease of application. These pull points ... secure the anterior closure of the garment. ...
... innovative, new padding system from Innovation Sports. ... and contours to the unique anatomy of ... Plus, Gel Fit's proprietary Octogrip™ Anti-Slip System ... seal when the brace is strapped on. ...
... the world's most versatile functional knee brace. ... or both, Flex is equipped for the ... control flexion and extension and its carbon ... heat-moldable to accommodate changes in leg shape ...
Medicine Products: